Business
enGene Appoints Ryan Daws as Chief Financial Officer
BOSTON and MONTREAL, Nov. 29, 2023 /PRNewswire/ - enGene Holdings Inc. ("enGene,") (NASDAQ: ENGN) (NASDAQ: ENGNW), a clinical-stage genetic medicines company
About this update from Engene Therapeutics Inc.
[{"type":"text","content":"BOSTON and MONTREAL, Nov. 29, 2023 /PRNewswire/ - enGene Holdings Inc. (\"enGene,\") (NASDAQ: ENGN) (NASDAQ: ENGNW), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment of Ryan Daws as Chief Financial Officer and Head of Business Development.\n\n \n \n \n \n \n \n\n \n\"I am delighted to welcome Ryan to enGene at a critical time in our growth, as we move forward as a public company and work to advance our ongoing pivotal-stage EG-70 clinical study in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC),\" said Jason D. Hanson, Chief Executive Officer of enGene. \"Ryan's significant experience across multiple areas of financial, business development and operational management in the pharmaceutical industry, as well as healthcare investment banking, complements our leadership team. We look forward to working with Ryan to continue to serve our shareholders, clinicians, and ultimately patients, in pursuit of our longstanding goal of mainstreaming gene therapy and bringing our genetic medicines to community clinics across the globe.\"\nMr. Daws joins enGene with nearly 25 years of life sciences-focused operational and deal-making experience. Prior to joining enGene, Mr. Daws was Chief Financial Officer and Head of Business Development at Obsidian Therapeutics, Inc. In that role, he was responsible for finance, business development, information technology, investor relations and facilities functions. Prior to joining Obsidian Therapeutics, Mr. Daws was Managing Director with the Healthcare Investment Banking Group at Robert W. Baird & Co., Inc. where he was responsible for IPOs, follow-on offerings, private placements and mergers and acquisition transactions in the life sciences sector. Mr. Daws also previously served as Chief Financial Officer and Head of Business Development at Concert Pharmaceuticals, Inc. Prior to Concert Pharmaceuticals, Mr. Daws spent nearly 15 years originating and executing equity and mergers and acquisitions transactions in the life sciences sector, first at Cowen and Company, LLC and then Stifel, Nicolaus & Co, Inc. Mr. Daws earned his International Master of Business Administration and Bachelor of Science in Business Administration from the University of South Carolina.\nMr...